- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report2015 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Tolerance of the anti-EGFR therapy2012 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Lung adenocarcinoma with a rare EGFR mutation and infrequent resistance to treatment2022 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Anti-EGFR treatment of colorectal cancer2021 | Publication without faculty affiliation
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Rechallenge with anti-EGFR therapy2023 | Third Faculty of Medicine
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Analysis of advancer NSCLC patients with prolonged progression-free survival after EGFR tyrosine kinase therapy2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Anti-EGFR therapy in colorectal carcinoma2017 | Publication without faculty affiliation
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine
- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Options and rationale for reinstituting anti-EGFR therapy in pretreated RAS wild-type advanced colorectal carcinomas2023 | Publication without faculty affiliation
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- Expression of EGFR and a copy count of EGFR gene in head andPublication without faculty affiliation
- Interdisciplinary consensus for predictive testing of activation mutations of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer2011 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Possibilities and substantiation of re-treatment with anti-EGFR drugs for pre-treated RAS wild-type advanced colorectal cancers2021 | Publication without faculty affiliation
- Expression of EGFR and a copy count of EGFR gene in head and neck cancer patientsPublication without faculty affiliation
- Effect of preoperative radiochemotherapy on rectal adenocarcinoma EGFR expression Effect of preoperative radiochemotherapy on rectal adenocarcinoma EGFR expression2012 | Faculty of Medicine in Hradec Králové
- Analytical background for precise eGFR estimation +12008 | Faculty of Medicine in Hradec Králové
- Analytical background for precise eGFR estimation2008 | First Faculty of Medicine
- Expression of EGFR in head and neck cancer patientsPublication without faculty affiliation
- Indication of EGFR Kinase Inhibitors Should Be Refined2011 | Third Faculty of Medicine
- Long-term response to sequential treatment with tyrosine kinase inhibitors in a patient with EGFR+ adenocarcinoma2021 | Third Faculty of Medicine
- Long-term surviving patient with EGFR mutation - deletion on exon 79 and acquired resistant mutation T790 - case report2020 | Faculty of Medicine in Pilsen
- Metastatic colorectal cancer and target EGFR inhibition with cetuximab2012 | Faculty of Medicine in Pilsen